2026-04-13T00:09:51Zhttps://recercat.cat/oai/requestoai:recercat.cat:11351/127442025-05-03T03:20:35Zcom_2072_378070com_2072_378040col_2072_378092
RECERCAT
author
Amaral, Teresa
author
Nanz, Lena
author
Serna-Higuita, Lina Maria
author
Berking, Carola
author
ASCIERTO, PAOLO ANTONIO
author
MUÑOZ COUSELO, EVA
2025-05-03T03:20:35Z
2025-05-03T03:20:35Z
2025-03-11T11:16:39Z2025-03-11T11:16:39Z20242025-01
http://hdl.handle.net/11351/12744
Checkpoint inhibitors; Overall survival; Targeted therapyInhibidores de puntos de control; Supervivencia global; Terapia dirigidaInhibidors de punts de control; supervivència global; Teràpia dirigidaBackground
Over the past decade, PD-1-based immune checkpoint inhibitors (ICI) and targeted therapies (TT) with BRAF and MEK inhibitors transformed melanoma treatment. Both are widely used in the adjuvant setting. However, for patients with a BRAF V600 mutation, the optimal adjuvant therapy remains unclear due to the lack of head-to-head comparison studies.
Methods
We conducted a systematic review of real-world data on adjuvant therapy in stage III melanoma to determine the best option for patients with BRAF V600 mutations. Kaplan-Meier curves were generated for TT and ICI using Digitizelt software.
Results
Nine publications with 3625 patients were included. TT showed better relapse-free survival (RFS) at 6, 12, 24, and 36 months than ICI. A similar trend was observed for distant metastasis-free survival (DMFS), with no apparent difference in overall survival.
Conclusion
Real-world data suggest that adjuvant TT may be associated with better RFS and DMFS in stage III BRAF V600-mutated melanoma compared to ICI.
Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess
Anomalies cromosòmiques
Melanoma - Immunoteràpia
Pell - Càncer - Immunoteràpia
Medicaments antineoplàstics - Ús terapèutic
Avaluació de resultats (Assistència sanitària)
PHENOMENA AND PROCESSES::Genetic Phenomena::Genetic Variation::Mutation
CHEMICALS AND DRUGS::Chemical Actions and Uses::Pharmacologic Actions::Therapeutic Uses::Antineoplastic Agents::Antineoplastic Agents, Immunological
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Therapeutics::Drug Therapy::Molecular Targeted Therapy
DISEASES::Neoplasms::Neoplasms by Histologic Type::Neoplasms::Neoplasms by Histologic Type::Neoplasms::Neoplasms by Histologic Type::Nevi and Melanomas::Melanoma
Other subheadings::Other subheadings::Other subheadings::/drug therapy
DISEASES::Neoplasms::Neoplasms by Site::Skin Neoplasms
ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Survival Analysis::Progression-Free Survival
FENÓMENOS Y PROCESOS::fenómenos genéticos::variación genética::mutación
COMPUESTOS QUÍMICOS Y DROGAS::acciones y usos químicos::acciones farmacológicas::usos terapéuticos::antineoplásicos::inmunoterapia antineoplásica
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::terapéutica::farmacoterapia::terapia molecular selectiva
ENFERMEDADES::neoplasias::neoplasias por tipo histológico::neoplasias::neoplasias por tipo histológico::neoplasias::neoplasias por tipo histológico::nevos y melanomas::melanoma
Otros calificadores::Otros calificadores::Otros calificadores::/farmacoterapia
ENFERMEDADES::neoplasias::neoplasias por localización::neoplasias cutáneas
TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS::técnicas de investigación::métodos epidemiológicos::estadística como asunto::análisis de supervivencia::supervivencia libre de progresión
A comparison of real-world data on adjuvant treatment in patients with stage III BRAF V600 mutated melanoma - Results of systematic literature research
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion